Updated on 2026/02/14

写真a

 
Yamamoto Shoichiro
 
Organization
University Hospital Assistant Professor
Title
Assistant Professor
Contact information
メールアドレス
External link

Degree

  • PhD in Medicine ( 2019.3   Ehime University )

Research Interests

  • Lung cancer

  • 呼吸器内科

  • 悪性腫瘍

  • 機械学習

Research Areas

  • Life Science / Respiratory medicine

Professional Memberships

▼display all

Committee Memberships

  • 日本臨床腫瘍学会   高齢者のがん薬物療法ガイドライン改訂第2版 SR委員  

    2024.4   

    　 More details

    Committee type：Academic society

    researchmap

  • NPO法人 中国・四国呼吸器疾患関連事業包括的支援機構CS-Lung   広報副委員長  

    2023.4   

    　 More details

    Committee type：Other

    researchmap

Qualification acquired

  • Medical license

Papers

  • Impact of immunotherapy on survival and treatment patterns of patients with extensive-stage small cell lung cancer: a study using a Japanese nationwide database.

    Ihara Y, Yamamoto S, Mizutani M, Okada N, Shimomura Y, Nogami N

    Future oncology (London, England)   22 ( 4 )   455 - 465   2026.2

    　More details

    Language：English  

    DOI： 10.1080/14796694.2026.2623038

    PubMed

  • Risk factors for lower adherence to epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer: A nationwide retrospective cohort study in Japan. International journal

    Yasutaka Ihara, Shoichiro Yamamoto, Megumi Mizutani, Shinji Akiyama, Naoto Okada, Yuki Shimomura

    Oncology   1 - 23   2025.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    INTRODUCTION: The prognosis of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (EGFR-m-NSCLC) has improved with the introduction of oral EGFR- tyrosine kinase inhibitor (TKI). Lower adherence to oral anticancer medications is reportedly associated with a poor prognosis. It is important to understand the causes of lower adherence to oral anticancer medications. We aimed to assess the potential risk factors associated with low adherence to EGFR-TKIs in a real-world clinical setting using administrative claims data in Japan. METHODS: We identified 10,809 outpatients routinely prescribed EGFR-TKIs between December 2015 and January 2023. Adherence to EGFR-TKIs was assessed based on the medication possession ratio (MPR) during the 12-month follow-up period from the date of first outpatient EGFR-TKI prescription. Multivariable linear regression analysis was performed to identify the potential risk factors associated with lower adherence. RESULTS: The mean (standard deviation) MPR was 94.1% (14.0). Lower adherence was associated with increasing age (per 10-year increase), female sex, dysphagia, and a higher number of concomitant oral medications (per doubling of the count). CONCLUSION: Adherence to EGFR-TKIs was generally high, but the findings support tailored adherence strategies, especially for older patients and for those with a higher number of concomitant oral medications, including medication review to reduce pill burden and proactive support for swallowing difficulties.

    DOI： 10.1159/000548812

    Scopus

    PubMed

    researchmap

  • Association Between Immunotherapy and Overall Survival in Malnourished Patients with Advanced Non-Small Cell Lung Cancer: A Nationwide Retrospective Cohort Study in Japan. International journal

    Maya Shimasaki, Yasutaka Ihara, Shoichiro Yamamoto, Haruki Takata, Shinji Akiyama

    Nutrition and cancer   78 ( 1 )   1 - 9   2025.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Malnutrition is common among patients with advanced non-small cell lung cancer (NSCLC) and may diminish the survival benefits of immunotherapy. We aimed to evaluate the association between nutritional status-assessed using the Geriatric Nutritional Risk Index (GNRI) at initiation of first-line therapy and overall survival in patients with advanced NSCLC receiving immunotherapy. METHODS: We conducted a retrospective cohort study using an administrative claims database. Patients aged ≥18 years who received first-line immunotherapy for newly diagnosed advanced NSCLC between December 2016 and December 2024 were included. GNRI was calculated using the laboratory and anthropometric data closest (within 3 months) to treatment initiation. To examine whether the GNRI modifies the association between immunotherapy as a first-line therapy and overall survival in patients with advanced NSCLC, we used nonlinear multivariable Cox proportional hazards regressions. RESULTS: Among 2461 patients (mean (SD) age: 70.85 (8.97) years; 81% males), the mean (SD) GNRI was 93.20 (12.93). Using GNRI 100 as the reference, lower GNRI values conferred progressively higher risks of death. CONCLUSION: Routine nutritional screening using GNRI and proactive interventions to maintain a GNRI ≥ 100, may improve overall survival in patients with advanced NSCLC receiving immunotherapy.

    DOI： 10.1080/01635581.2025.2569118

    Scopus

    PubMed

    researchmap

  • Eosinophilic fasciitis induced by immune checkpoint inhibitors successfully controlled with dapsone. International journal

    Satoshi Tsuboi, Satoshi Yoshida, Kazuki Yatsuzuka, Nobushige Kohri, Katsuhiko Nishihara, Shoichiro Yamamoto, Jun Muto, Ken Shiraishi, Yasuhiro Fujisawa

    European journal of dermatology : EJD   35 ( 1 )   58 - 60   2025.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1684/ejd.2025.4825

    Scopus

    PubMed

    researchmap

  • Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA Reviewed

    E. Felip, B.C. Cho, V. Gutiérrez, A. Alip, B. Besse, S. Lu, A.I. Spira, N. Girard, R. Califano, S.M. Gadgeel, J.C.-H. Yang, S. Yamamoto, K. Azuma, Y.J. Kim, K.-H. Lee, P. Danchaivijitr, C.G. Ferreira, Y. Cheng, M.A.N. Sendur, G.-C. Chang, C.-C. Wang, K. Prabhash, Y. Shinno, D. Stroyakovskiy, L. Paz-Ares, J.R. Rodriguez-Cid, C. Martin, M.R.G. Campelo, H. Hayashi, D. Nguyen, P. Tomasini, M. Gottfried, C. Dooms, A. Passaro, M. Schuler, A.C.Z. Gelatti, S. Owen, K. Perdrizet, S.-H.I. Ou, J.C. Curtin, J. Zhang, M. Gormley, T. Sun, A. Panchal, M. Ennis, E. Fennema, M. Daksh, S. Sethi, J.M. Bauml, S.-H. Lee

    Annals of Oncology   35 ( 9 )   805 - 816   2024.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    DOI： 10.1016/j.annonc.2024.05.541

    Scopus

    PubMed

    researchmap

  • Corrigendum to "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy" [Lung Cancer 177 (2023) 44-50]. International journal

    Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, Motoko Tachihara, Daichi Fujimoto, Hidetoshi Hayashi, Kakuhiro Yamaguchi, Shoichiro Yamamoto, Eiji Iwama, Koichi Azuma, Kazuo Hasegawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa

    Lung cancer (Amsterdam, Netherlands)   193   107852 - 107852   2024.7

    　More details

  • Distinguishing Axillary Lymphadenopathy after COVID-19 Vaccination from Malignant Lymphadenopathy. International journal

    Shintaro Yamanaka, Keiko Tanaka, Masao Miyagawa, Teruhito Kido, Shinji Hasebe, Shoichiro Yamamoto, Tomomi Fujii, Kazuto Takeuchi, Yoshihiro Yakushijin

    Journal of clinical medicine   13 ( 12 )   2024.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Objectives: To study the differences between malignant hypermetabolic axillary lymphadenopathy (MHL) and COVID-19 vaccine-associated axillary hypermetabolic lymphadenopathy (VAHL) using clinical imaging. Methods: A total of 1096 patients underwent Positron Emission Tomography-Computed Tomography (PET-CT) between 1 June 2021 and 30 April 2022 at Ehime University Hospital. In total, 188 patients with axillary lymphadenopathy after the COVID-19 vaccination were evaluated. The patients were classified into three groups such as VAHL (n = 27), MHL (n = 21), and equivocal hypermetabolic axillary lymphadenopathy (EqHL; n = 140). Differences in lymph node (LN) swellings were statistically analyzed using clinical imaging (echography, CT, and 18F-FDG PET). Results: MHL included a higher female population (90.5%) owing to a higher frequency of breast cancer (80.9%). Axillary LNs of MHL did not show any LN fatty hilums (0%); however, those of VAHL and EqHL did (15.8 and 36%, respectively). After the logistic regression analysis of the patients who had axillary lymphadenopathy without any LN fatty hilums, the minor axis length and ellipticity (minor axis/major axis) in the largest axillary LN, SUVmax, and Tissue-to-Background Ratio (TBR) were useful in distinguishing malignant lymphadenopathies. A receiver-operating characteristic (ROC) analysis indicated that a cut-off value of ≥7.3 mm for the axillary LN minor axis (sensitivity: 0.714, specificity: 0.684) and of ≥0.671 for ellipticity (0.667 and 0.773, respectively) in the largest LN with the highest SUVmax and TBR were predictive of MHL. Conclusions: Axillary lymphadenopathy of the minor axis and ellipticity in LN without fatty hilums may be useful to be suspicious for malignancy, even in patients who have received COVID-19 vaccination. Further examinations, such as 18F-FDG PET, are recommended for such patients.

    DOI： 10.3390/jcm13123387

    Scopus

    PubMed

    researchmap

  • Visual Turing test is not sufficient to evaluate the performance of medical generative models. International journal

    Shoichiro Yamamoto, Akinori Higaki

    European radiology experimental   7 ( 1 )   31 - 31   2023.7

    　More details

  • A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. International journal

    Masayuki Takeda, Mototsugu Shimokawa, Atsushi Nakamura, Kaname Nosaki, Yasutaka Watanabe, Terufumi Kato, Daisuke Hayakawa, Hiroshi Tanaka, Toshiaki Takahashi, Masahide Oki, Motoko Tachihara, Daichi Fujimoto, Hidetoshi Hayashi, Kakuhiro Yamaguchi, Shoichiro Yamamoto, Eiji Iwama, Koichi Azuma, Kazuo Hasegawa, Nobuyuki Yamamoto, Kazuhiko Nakagawa

    Lung cancer (Amsterdam, Netherlands)   177   44 - 50   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is an established standard treatment option for chemotherapy-naive patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). However, of such patients who have received prior treatment with a first- or second-generation EGFR TKI, only approximately half are eligible for osimertinib therapy because its indication as second-line treatment and beyond is limited to metastatic NSCLC that is positive for the T790M resistance mutation of the EGFR gene. This study was initiated at the request of a dedicated network for patients with lung cancer in Japan. METHODS: We conducted a phase II study to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy. The primary end point was response rate (assessed by a central imaging reviewer). RESULTS: From August 2020 to February 2021, 55 patients from 15 institutions were enrolled in the study. The overall response for primary analysis was achieved in 16 patients (29.1 %; 95 % CI, 17.6-42.9), which exceeded the threshold response rate necessary for analysis. Stable disease was found in 16 patients (29.1 %), and progressive disease, in 18 (32.7 %). The median length of progression-free survival (PFS) was 4.07 months (95 % CI 2.10-4.30), and the rate of 12-month PFS was 17.3 %. CONCLUSIONS: Osimertinib demonstrated modest antitumor activity against progressive EGFR T790M-negative disease.

    DOI： 10.1016/j.lungcan.2023.01.011

    Scopus

    PubMed

    researchmap

  • Use of the forced-oscillation technique to estimate spirometry values Reviewed International journal

    Shoichiro Yamamoto, Seigo Miyoshi, Hitoshi Katayama, Mikio Okazaki, Hisayuki Shigematsu, Yoshifumi Sano, Minoru Matsubara, Naohiko Hamaguchi, Takafumi Okura, Jitsuo Higaki

    International Journal of Chronic Obstructive Pulmonary Disease   Volume 12   2859 - 2868   2017.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Informa UK Limited  

    PURPOSE: Spirometry is sometimes difficult to perform in elderly patients and in those with severe respiratory distress. The forced-oscillation technique (FOT) is a simple and noninvasive method of measuring respiratory impedance. The aim of this study was to determine if FOT data reflect spirometric indices. PATIENTS AND METHODS: Patients underwent both FOT and spirometry procedures prior to inclusion in development (n=1,089) and validation (n=552) studies. Multivariate linear regression analysis was performed to identify FOT parameters predictive of vital capacity (VC), forced VC (FVC), and forced expiratory volume in 1 second (FEV1). A regression equation was used to calculate estimated VC, FVC, and FEV1. We then determined whether the estimated data reflected spirometric indices. Agreement between actual and estimated spirometry data was assessed by Bland-Altman analysis. RESULTS: Significant correlations were observed between actual and estimated VC, FVC, and FEV1 values (all r>0.8 and P<0.001). These results were deemed robust by a separate validation study (all r>0.8 and P<0.001). Bias between the actual data and estimated data for VC, FVC, and FEV1 in the development study was 0.007 L (95% limits of agreement [LOA] 0.907 and -0.893 L), -0.064 L (95% LOA 0.843 and -0.971 L), and -0.039 L (95% LOA 0.735 and -0.814 L), respectively. On the other hand, bias between the actual data and estimated data for VC, FVC, and FEV1 in the validation study was -0.201 L (95% LOA 0.62 and -1.022 L), -0.262 L (95% LOA 0.582 and -1.106 L), and -0.174 L (95% LOA 0.576 and -0.923 L), respectively, suggesting that the estimated data in the validation study did not have high accuracy. CONCLUSION: Further studies are needed to generate more accurate regression equations for spirometric indices based on FOT measurements.

    DOI： 10.2147/copd.s143721

    Scopus

    PubMed

    researchmap

  • モストグラフは肺活量、1秒量を予測する

    三好 誠吾, 山本 千恵, 山本 将一郎, 仙波 真由子, 濱田 千鶴, 片山 均, 岡崎 幹生, 重松 久之, 佐野 由文, 大蔵 隆文, 檜垣 實男

    日本呼吸器学会誌   5 ( 増刊 )   289 - 289   2016.3

    　More details

    Language：Japanese   Publisher：(一社)日本呼吸器学会  

    researchmap

  • [Pulmonary non-tuberculous mycobacteriosis complicated with lung cancer].

    Hiroshi Suehisa, Fumio Matsuda, Hiroaki Kawamoto, Tsuyoshi Ueno, Shigeki Sawada, Motohiro Yamashita, Shoichiro Yamamoto, Daijiro Harada, Hiromoto Kitajima, Toshiyuki Kozuki, Naoyuki Nogami, Hiroyuki Takahata

    Kyobu geka. The Japanese journal of thoracic surgery   67 ( 7 )   549 - 52   2014.7

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

    A 54-year-old man with pulmonary non-tuberculous mycobacteriosis( pulmonary NTM) who had been treated by antituberculous chemotherapy, developed a new nodule of 1.3 cm in size in the segment 1/2 of the right upper lobe. The cavity of 3.5 cm in size in the segment 6 of the right lower lobe from which Mycobacterium intracellulare was bronchoscopically detected, was suspected to be pulmonary NTM lesion. Since lung cancer was highly suspected by radiological examinations, right upper lobectomy and S6 segmentectomy were performed. Pathological diagnosis for the right upper lobe nodule was adenocarcinoma.

    PubMed

    researchmap

▼display all

Books

MISC

▼display all

Presentations

  • びまん性肺胞出血における予後因子(免疫性/非免疫性)の検討　単施設後ろ向き研究

    中村 行宏, 福西 宥希, 八木 貴寛, 菊池 泰輔, 田口 禎浩, 山本 哲也, 加藤 高英, 山本 将一朗, 野上 尚之, 山口 修

    日本呼吸器学会誌  2025.3  (一社)日本呼吸器学会

    　More details

    Language：Japanese  

  • トラマドールから強オピオイドへのオピオイドスイッチングする際の換算に影響を与える因子の検討

    清水 瞭子, 山中 伸太郎, 山本 将一朗, 長谷部 晋士, 山下 登, 飛鷹 範明, 藤井 知美, 薬師神 芳洋, 藤井 知美

    Palliative Care Research  2024.6  (NPO)日本緩和医療学会

    　More details

    Language：Japanese  

  • 他院で化学療法中の難治性癌性疼痛に対しクモ膜下フェノールブロックを施行した2症例

    山中 伸太郎, 藤井 知美, 堀田 三希子, 平川 美佳子, 西川 裕喜, 渡邊 愛沙, 藤岡 志帆, 中村 伸子, 長谷部 晋士, 山本 将一朗, 薬師神 芳洋

    日本癌治療学会学術集会抄録集  2024.10  (一社)日本癌治療学会

    　More details

    Language：English  

  • 当院におけるEBUS-GS施行後追加TBBの検討

    中村 行宏, 福西 宥希, 八木 貴寛, 菊池 泰輔, 田口 禎浩, 山本 哲也, 加藤 高英, 山本 将一朗, 野上 尚之, 山口 修

    気管支学  2025.5  (一社)日本呼吸器内視鏡学会

    　More details

    Language：Japanese  

  • 当院の線維性過敏性肺炎診断における抗体検査の検証

    中村 行宏, 茅田 祐輝, 八木 貴寛, 菊池 泰輔, 田口 禎浩, 山本 哲也, 加藤 高英, 山本 将一朗, 濱口 直彦, 野上 尚之, 山口 修

    日本呼吸器学会誌  2024.3  (一社)日本呼吸器学会

    　More details

    Language：Japanese  

  • 気管支鏡で空洞内の菌球を直視し,治療方針に寄与できた慢性進行性肺アスペルギルス症の1例

    山本 将一朗, 茅田 祐輝, 八木 貴寛, 菊池 泰輔, 田口 禎浩, 中村 行宏, 山本 哲也, 加藤 高英, 野上 尚之, 山口 修

    気管支学  2024.5  (一社)日本呼吸器内視鏡学会

    　More details

    Language：Japanese  

  • 限局型小細胞肺癌に対する放射線化学療法におけるCDDP+ETP療法とCBDCA+ETP療法の比較

    福西 宥希, 中村 行宏, 八木 貴寛, 菊池 泰輔, 田口 禎浩, 山本 哲也, 加藤 高英, 山本 将一朗, 野上 尚之, 山口 修

    日本呼吸器学会誌  2025.3  (一社)日本呼吸器学会

    　More details

    Language：Japanese  

  • 骨軟骨肉腫の骨盤内再発により生じた難治性がん疼痛の一例

    藤井 知美, 渡邊 愛沙, 藤岡 志帆, 塩崎 亜由生, 林 博美, 長谷部 晋士, 山中 伸太郎, 山本 将一朗, 木谷 彰岐, 薬師神 芳洋

    Palliative Care Research  2024.11  (NPO)日本緩和医療学会

    　More details

    Language：Japanese  

  • これからの気管支鏡検査ROSEに求められる多様性　臨床医が診る"なんちゃってROSE"の改善の訴求

    野上 尚之, 山本 将一朗, 中村 行宏, 有安 早苗, 北澤 理子, 佐藤 正和

    日本臨床細胞学会雑誌  2024.5  (公社)日本臨床細胞学会

    　More details

    Language：Japanese  

▼display all

Teaching Experience

  • 呼吸器内科学

    2021 Institution：愛媛大学

    　More details